|
|
|
| Effects of Ambroxol Hydrochloride combined with Montelukast Sodium on Serum Levels of MMP-9 TIMP-1 and IL-6 in Children with Asthma |
| LU Fang, ZHU Yan |
| Jingmen Second People's Hospital, Hubei Jingmen 448000, China |
|
|
|
|
Abstract Objective:To explore the different administration routes of ambroxol hydrochloride combined with montelukast sodium om serum levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1(TIMP-1) and interleukin-6 (IL-6) in children patients with asthma. Methods:84 cases of children patients with asthma admitted to our hospital were evenly divided into atomization group and intravenous drip group according to the random number table method. On the basis of conventional treatment and montelukast sodium chewable tablets, atomization group was given atomization inhalation of ambroxol hydrochloride, and intravenous drip group was given intravenous drip of ambroxol hydrochloride. Clinical efficacy, disappearance times of symptoms and signs, pulmonary ventilation function and serum markers were compared between the two groups. Results:After treatment, the total effective rate in atomization group was significantly higher than that in intravenous drip group (95.24% vs 76.19%) (P<0.05). The disappearance times of fever, asthma, cough and lung rale in atomization group were earlier than that in intravenous drip group (P<0.05). There were no significant differences in the levels of pulmonary artery resistance index (RI), pulmonary shunt rate (Qs/Qt), partial pressure difference of alveolar-arterial oxygen (PA-aDO2), maximal inspiratory pressure (PIMAX), serum MMP-9, TIMP-1, IL-6 and osteopontin (OPN) between the two groups before treatment (P>0.05), but the differences of above indexes before and after treatment in atomization group were greater than those in intravenous drip group (P<0.05). Conclusions: Ambroxol hydrochloride combined with montelukast sodium can effectively control the condition of children with asthma, and the efficacy of aerosol inhalation is better than intravenous drip, which may be related to the reduction of serum levels of MMP-9, TIMP-1, IL-6 and OPN.
|
|
|
|
|
|
[1] 王亚琴,蔡海燕,杨夏,等.支气管哮喘患儿行为特征的研究[J].医学临床研究,2017,34(7):1393~1394.
[2] 饶敏,李娟.舒利迭与吸入性糖皮质激素联合孟鲁司特钠治疗儿童中度持续性哮喘的疗效对比研究[J].湖南师范大学学报(医学版),2016,13(3):123~126.
[3] 陈楠,李晓华,刘平,等.盐酸氨溴索雾化吸入与静脉注射的临床药代动力学和药效学研究[J].医学研究杂志,2016,45(1):113~116.
[4] 中华医学会儿科学分会呼吸学组.儿童支气管哮喘诊断与防治指南(2016年版)[J].中华儿科杂志,2016,54(3):167~181.
[5] 林亚发,程宏宁.氨溴索联合孟鲁斯特钠治疗难治性哮喘的效果观察[J].医学综述,2016,22(15):3084~3087.
[6] 彭芬,黄华,钱炜.糖皮质激素对哮喘患儿的临床疗效及作用机制研究[J].中国临床药理学杂志,2016,32(1):3~5.
[7] 邵双珠.孟鲁斯特钠联合布地奈德治疗缓解期哮喘患儿临床疗效评估[J].临床肺科杂志,2016,21(03):556~558.
[8] 杜春华,黎家金,廖全辉.盐酸氨溴索联合止咳平喘糖浆治疗小儿咳嗽的临床研究[J].药物评价研究,2017,40(8):1117~1121.
[9] 马振勇,刘克祥,张建军.AECOPD患者盐酸氨溴索静脉滴注与雾化的效果差异[J].河北医药,2017,39(16):2451~2454.
[10] 王芳,贾莹莹,杨臻,等.加味射干麻黄汤治疗哮喘患儿的临床评价及对血清TGF-β-1、NGF、白介素族及肺换气功能的影响[J].中药材,2017,40(08):1969~1971. |
|
|
|
2019, Vol. 25 
